Advertisement

Topics

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

2014-08-27 03:14:52 | BioPortfolio

Summary

RATIONALE: Dinaciclib may stop the growth of cancer cells by clocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.

Description

OBJECTIVES:

Primary

- To evaluate the efficacy of single agent dinaciclib in patients with relapsed or refractory multiple myeloma.

Secondary

- To evaluate the toxicities associated with dinaciclib in these patients.

- To evaluate the response duration and progression-free survival among these patients.

- To study the effect of dinaciclib on myeloma cell proliferation and apoptotic rates.

- To assess the ability of dinaciclib to inhibit drug targets (cyclin-dependent kinases in the myeloma cell).

OUTLINE: This is a multicenter, dose escalation study.

Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Blood and bone marrow samples are collected periodically for correlative studies.

After completion of study treatment, patients are followed up for up to 3 years.

Study Design

Primary Purpose: Treatment

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Intervention

dinaciclib, laboratory biomarker analysis

Location

Mayo Clinic Cancer Center
Rochester
Minnesota
United States
55905

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:14:52-0400

Clinical Trials [4304 Associated Clinical Trials listed on BioPortfolio]

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned a...

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned a...

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer ...

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. ...

Dinaciclib in Treating Patients With Stage III or Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

RATIONALE: Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose ...

PubMed Articles [40249 Associated PubMed Articles listed on BioPortfolio]

Flow Cytometric Aberrancies in Plasma Cell Myeloma and MGUS - Correlation with Laboratory Parameters.

Multiparametric flow cytometry (MFC) is a useful tool for diagnosis of plasma cell dyscrasias and assessment of minimal residual disease (MRD) in plasma cell myeloma (PCM). However, the immunophenotyp...

Cold atmospheric plasma as a potential tool for multiple myeloma treatment.

Multiple myeloma (MM) is a fatal and incurable hematological malignancy thus new therapy need to be developed. Cold atmospheric plasma, a new technology that could generate various active species, cou...

Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma.

Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker ...

Multiple Myeloma: The Case of the Disappearing Band.

This case study presents a patient with multiple myeloma whose serum specimen exhibits 2 distinct bands in serum protein electrophoresis but only one band in immunofixation electrophoresis. This latte...

Functional and molecular MRI of the bone marrow in multiple myeloma.

MRI plays an important role in the management of patients with plasma cell neoplasms and has been recognized as a biomarker of malignancy in the novel criteria for the diagnosis of multiple myeloma. F...

Medical and Biotech [MESH] Definitions

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.

More From BioPortfolio on "Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial